Provention Bio
United States
188 articles about Provention Bio
-
Provention Bio Announces the Grant of Inducement Awards - June 02, 2021
6/2/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to two new employees to purchase an aggregate of 40,000 shares of common stock.
-
Provention Bio to Present at the Jefferies Virtual Healthcare Conference - June 01, 2021
6/1/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 AM E.T.
-
The question before the committee was whether the benefits of teplizumab outweigh the risks as it voted 10-7 in favor of the drug to delay clinical type 1 diabetes mellitus.
-
Provention Bio Stock Trading Halted Today
5/27/2021
-- FDA Advisory Committee to Review Biologics License Application for PRV-031 for the Delay of Clinical Type 1 Diabetes --
-
Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab
5/25/2021
Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced today that the U.S. Food and Drug Administration (FDA) posted briefing documents for the May 27, 2021 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)
-
It’s a busy week for the U.S. Food and Drug Administration, with a number of drug approvals on the calendar and an advisory committee meeting. Read on for more information.
-
Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
5/6/2021
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results and provided a business update for the first quarter ended March 31, 2021 .
-
Provention Bio Announces the Grant of Inducement Awards
5/3/2021
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 22 new employees to purchase an aggregate of 423,800 shares of common stock.
-
Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021
4/29/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets.
-
Provention Bio Provides Additional Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
4/27/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced the Company took part in an informal meeting with the U.S. Food and Drug Administration on April 23, 2021, in connection with the FDA's ongoing review of the teplizumab Biologic License Application for the delay or prevention of clinical type 1 diabetes.
-
Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
4/8/2021
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company's Biologic License Application (BLA) for teplizumab
-
Provention Bio to Present at Two Upcoming Virtual Investor Conferences
3/4/2021
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in two upcoming virtual investor conferences in March.
-
Provention Bio Announces Publication of Extended Follow-up Data from the Pivotal "At-Risk" TN-10 Study of Teplizumab in Science Translational Medicine
3/3/2021
One course of teplizumab delayed insulin dependence by approximately three years and improved beta cell function in at-risk (Stage 2) type 1 diabetes patients
-
Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
2/25/2021
-U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals; PDUFA goal date of July 2, 2021-
-
Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
2/18/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that it will report its fourth quarter and full year 2020 financial results on February 25, 2021 before the opening of the U.S. financial markets.
-
Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China
2/17/2021
- Provention Bio to receive $6 million upfront payment; up to $11.5 million in research, development and manufacturing funding; and up to $172 million in potential development, regulatory and commercial milestone payments -
-
Provention Bio Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy
1/28/2021
- PRV-3279 Murine Surrogate Inhibited the Production of Anti-adenoviral Vector Antibodies in a Mouse Model for Pompe Disease - - Rapid, Robust and Reversible B cell Inhibition Suggest PRV-3279 Could Become an Adjunctive Co-Treatment with Gene Therapy -
-
Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock
1/13/2021
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share
-
Provention Bio Announces Proposed Public Offering of Common Stock - Jan 12, 2021
1/12/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock.
-
Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference
1/6/2021
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021 .